Spots Global Cancer Trial Database for Quality Of Life and Drug Use in Patients With CAR-T Cells

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Quality Of Life and Drug Use in Patients With CAR-T Cells

Official Title: Pilot Study for Quality Of Life and Drug Use Assessment in Patients With CAR-T Cells

Study ID: NCT04914091

Conditions

Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells

Interventions

Semi-structured interviews and self-administered questionnaires

Study Description

Brief Summary: CAR-T cells are a major therapeutic innovation in the management of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in 3rd line or more. Kymriah® and Yescarta® are the first CAR-T with Marketing Authorization and coverage by the French Health Insurance. Their clinical interest has been demonstrated in non-comparative phase 1-2 trials. The non-comparative design of the pivotal trials, the lack of data on patients' quality of life and drug consumption, as well as the very high cost of CAR-T (about € 320,000 for one treatment) warrant further studies. This prospective non-comparative study aims to describe in real life the quality of life of patients treated with CAR-T cells, real world drug use and patients' experience feedback.

Detailed Description: